Review



gene exp cd34 hs00156373 m1  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Thermo Fisher gene exp cd34 hs00156373 m1
    List of Predesigned Taqman ® Probes for QPCR (Applied Biosystems)
    Gene Exp Cd34 Hs00156373 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/Gene+Exp%2E+CD34%2C+Hs00156373_m1/pmc03143417-8-0--1
    Average 90 stars, based on 1 article reviews
    gene exp cd34 hs00156373 m1 - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Subfractionation of Differentiating Human Embryonic Stem Cell Populations Allows the Isolation of a Mesodermal Population Enriched for Intermediate Mesoderm and Putative Renal Progenitors"

    Article Title: Subfractionation of Differentiating Human Embryonic Stem Cell Populations Allows the Isolation of a Mesodermal Population Enriched for Intermediate Mesoderm and Putative Renal Progenitors

    Journal: Stem Cells and Development

    doi: 10.1089/scd.2010.0017

    List of Predesigned Taqman ® Probes for QPCR (Applied Biosystems)
    Figure Legend Snippet: List of Predesigned Taqman ® Probes for QPCR (Applied Biosystems)

    Techniques Used: Variant Assay, Wilms Tumor Assay

    Microarray analyses of undifferentiated, unfractionated, and sorted fractions. (A) Heat maps of undifferentiated, unfractionated, and sorted fractions. Combined heat map of 3 biological replicates shows down-regulation of stem cell genes (yellow) and up-regulation of developmental genes (blue) across the undifferentiated (UD), unfractionated (UF), +Low, and ++− fractions. All 3 replicates show similar expression patterns of pluripotent and developmental genes confirming the reproducibility of the array results. (B) Gene ontology analyses performed on the top 1,000 up-regulated genes (B-stat > 0) in the ++− compared with the undifferentiated fraction show a slight increase in percentage of kidney and vascular development-associated genes in the ++− fraction relative to either spontaneously differentiated embryonic stem (ES) cells or cell populations derived from varying stem cell marker expression-based fractionation (red arrowheads). Ontology analysis also indicated a reduced proportion of genes involved in neural and skeletal muscle development in the ++− cell fraction (black arrowheads). (C) Cluster analyses. (a) Cluster analysis of the top 200 up-regulated genes in the ++− fraction compared with undifferentiated ES cells cross-matched with a genitourinary development-specific gene expression database (GUDMAP) shows an overrepresentation of transcripts associated with E11.5 murine metanephric interstitium (green box) and E15.5 nephrogenic and cortical interstitium (yellow box). (b) This overrepresentation was not observed when a randomly generated list of genes was subjected to the same cross-match. (c) Cluster analysis performed on all genes up-regulated only in ++− compared with undifferentiated, spontaneously differentiated, and ++Low fractions shows these genes are associated with the MM at E11.5 (green box), podocytes at E13.5 and E15.5 (yellow box), and the collecting duct and proximal tubules (purple box) when cross-matched with the GUDMAP database.
    Figure Legend Snippet: Microarray analyses of undifferentiated, unfractionated, and sorted fractions. (A) Heat maps of undifferentiated, unfractionated, and sorted fractions. Combined heat map of 3 biological replicates shows down-regulation of stem cell genes (yellow) and up-regulation of developmental genes (blue) across the undifferentiated (UD), unfractionated (UF), +Low, and ++− fractions. All 3 replicates show similar expression patterns of pluripotent and developmental genes confirming the reproducibility of the array results. (B) Gene ontology analyses performed on the top 1,000 up-regulated genes (B-stat > 0) in the ++− compared with the undifferentiated fraction show a slight increase in percentage of kidney and vascular development-associated genes in the ++− fraction relative to either spontaneously differentiated embryonic stem (ES) cells or cell populations derived from varying stem cell marker expression-based fractionation (red arrowheads). Ontology analysis also indicated a reduced proportion of genes involved in neural and skeletal muscle development in the ++− cell fraction (black arrowheads). (C) Cluster analyses. (a) Cluster analysis of the top 200 up-regulated genes in the ++− fraction compared with undifferentiated ES cells cross-matched with a genitourinary development-specific gene expression database (GUDMAP) shows an overrepresentation of transcripts associated with E11.5 murine metanephric interstitium (green box) and E15.5 nephrogenic and cortical interstitium (yellow box). (b) This overrepresentation was not observed when a randomly generated list of genes was subjected to the same cross-match. (c) Cluster analysis performed on all genes up-regulated only in ++− compared with undifferentiated, spontaneously differentiated, and ++Low fractions shows these genes are associated with the MM at E11.5 (green box), podocytes at E13.5 and E15.5 (yellow box), and the collecting duct and proximal tubules (purple box) when cross-matched with the GUDMAP database.

    Techniques Used: Microarray, Expressing, Derivative Assay, Marker, Fractionation, Gene Expression, Generated

    Validation of microarray results by quantitative polymerase chain reaction (PCR). Results of the microarray were validated by quantitative PCR screen of genes involved in the development of each compartment of the mesoderm where expression levels were first normalized against 18S rRNA and calibrated using a CD30-expressing human embryonic stem (ES) cell line as an internal standard. The QPCR results demonstrated a slight up-regulation in transcript levels of all 3 intermediate mesoderm and 2 lateral mesoderm genes, CD34 and CDH5, in the ++− fraction compared with the other 3 fractions, indicating that cells expressing these transcripts are enriched from the unfractionated cell population by sorting based on CD24+/Podo+/GCTM2−. Conversely, an overall lower level of gene expression was observed for paraxial mesoderm genes, which also showed little variation in transcript abundance across the cellular fractions, indicating that the cells that express these genes are not selectively isolated by sorting with the above markers. Values are presented as means ± SEM, n = 3.
    Figure Legend Snippet: Validation of microarray results by quantitative polymerase chain reaction (PCR). Results of the microarray were validated by quantitative PCR screen of genes involved in the development of each compartment of the mesoderm where expression levels were first normalized against 18S rRNA and calibrated using a CD30-expressing human embryonic stem (ES) cell line as an internal standard. The QPCR results demonstrated a slight up-regulation in transcript levels of all 3 intermediate mesoderm and 2 lateral mesoderm genes, CD34 and CDH5, in the ++− fraction compared with the other 3 fractions, indicating that cells expressing these transcripts are enriched from the unfractionated cell population by sorting based on CD24+/Podo+/GCTM2−. Conversely, an overall lower level of gene expression was observed for paraxial mesoderm genes, which also showed little variation in transcript abundance across the cellular fractions, indicating that the cells that express these genes are not selectively isolated by sorting with the above markers. Values are presented as means ± SEM, n = 3.

    Techniques Used: Biomarker Discovery, Microarray, Real-time Polymerase Chain Reaction, Expressing, Gene Expression, Isolation



    Similar Products

    96
    Miltenyi Biotec cd34 fraction
    Cd34 Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34+MicroBead+Kit+UltraPure%2C+human/bio_rxiv__64898__2025__12__22__695871-246-1-6
    Average 96 stars, based on 1 article reviews
    cd34 fraction - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd34 cell fractions
    Cd34 Cell Fractions, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34-VioBlue/us12203096-489-17-31
    Average 99 stars, based on 1 article reviews
    cd34 cell fractions - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd34 cell fraction
    Cd34 Cell Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34-VioBlue/pm39277669-53-1-17
    Average 99 stars, based on 1 article reviews
    cd34 cell fraction - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    99
    Qiagen cd34 cell fraction
    Cd34 Cell Fraction, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/miRNeasy+Micro+Kit/pmc11604037-358-7-18
    Average 99 stars, based on 1 article reviews
    cd34 cell fraction - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    90
    Glaxo Smith autologous cd34+-enriched cell fraction strimvelis
    FDA/EMA approved gene therapy product for rare monogenic diseases
    Autologous Cd34+ Enriched Cell Fraction Strimvelis, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/strimvelis/pmc11222908-222-7-8
    Average 90 stars, based on 1 article reviews
    autologous cd34+-enriched cell fraction strimvelis - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    Image Search Results


    FDA/EMA approved gene therapy product for rare monogenic diseases

    Journal: Clinical and Experimental Pediatrics

    Article Title: Development of orphan drugs for rare diseases

    doi: 10.3345/cep.2023.00535

    Figure Lengend Snippet: FDA/EMA approved gene therapy product for rare monogenic diseases

    Article Snippet: For instance, an autologous CD34+-enriched cell fraction, Strimvelis (GlaxoSmithKline plk, London, UK), which contains CD34+ cells transduced with a retroviral vector that encodes the human ADA cDNA sequence for ADA deficiency (introduced in 2016), and voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics, Philadelphia, USA), for retinal dystrophy caused by mutations in the RPE65 gene, were approved by the FDA in 2017 at a cost of $850,000 per eye [ ].

    Techniques: Plasmid Preparation, In Vivo, Ex Vivo, Mutagenesis, Modification, Variant Assay